Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Galy

Showing results (71-80 of 108) with videos related to

Pageof 11
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 20, 2005
A partial down-regulation of WASP is sufficient to inhibit podosome formation in dendritic cellsAurelie Olivier, Laurence Jeanson-Leh, Gerben Bouma, et al.
Blood|July 10, 2004
NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCsChristophe Borg, Abdelali Jalil, Diego Laderach, et al.
Acta Biomaterialia|October 12, 2017
Vectofusin-1, a potent peptidic enhancer of viral gene transfer forms pH-dependent α-helical nanofibrils, concentrating viral particlesLouic S Vermeer, Loic Hamon, Alicia Schirer, et al.
JCI Insight|February 18, 2026
Inter-individual variability in immune response to AAV ocular gene delivery across species impedes immunomonitoringDuohao Ren, Gaelle A Chauveau, Julie Vendomele, et al.
Human Gene Therapy. Clinical Development|April 18, 2018
Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous DiseaseChristian Brendel, Michael Rothe, Giorgia Santilli, et al.
Molecular Therapy. Methods & Clinical Development|November 14, 2019
Biosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene Therapy of Artemis-SCIDSabine Charrier, Chantal Lagresle-Peyrou, Valentina Poletti, et al.
Human Gene Therapy|November 4, 2010
Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy applicationOtto-Wilhelm Merten, Sabine Charrier, Nicolas Laroudie, et al.
Ophthalmology|February 11, 2018
Safety of rAAV2/2-ND4 Gene Therapy for Leber Hereditary Optic NeuropathyCatherine Vignal, Scott Uretsky, Serge Fitoussi, et al.
Human Gene Therapy|October 4, 2019
Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System ManufacturingConstanze Radek, Ornellie Bernadin, Katharina Drechsel, et al.
The Journal of Biological Chemistry|September 25, 2003
GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptorCaroline Diveu, Eric Lelièvre, David Perret, et al.
Pageof 11

Showing results (71-80 of 108) with videos related to

Sort By:
Pageof 11
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 20, 2005
A partial down-regulation of WASP is sufficient to inhibit podosome formation in dendritic cellsAurelie Olivier, Laurence Jeanson-Leh, Gerben Bouma, et al.
Blood|July 10, 2004
NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCsChristophe Borg, Abdelali Jalil, Diego Laderach, et al.
Acta Biomaterialia|October 12, 2017
Vectofusin-1, a potent peptidic enhancer of viral gene transfer forms pH-dependent α-helical nanofibrils, concentrating viral particlesLouic S Vermeer, Loic Hamon, Alicia Schirer, et al.
JCI Insight|February 18, 2026
Inter-individual variability in immune response to AAV ocular gene delivery across species impedes immunomonitoringDuohao Ren, Gaelle A Chauveau, Julie Vendomele, et al.
Human Gene Therapy. Clinical Development|April 18, 2018
Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous DiseaseChristian Brendel, Michael Rothe, Giorgia Santilli, et al.
Molecular Therapy. Methods & Clinical Development|November 14, 2019
Biosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene Therapy of Artemis-SCIDSabine Charrier, Chantal Lagresle-Peyrou, Valentina Poletti, et al.
Human Gene Therapy|November 4, 2010
Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy applicationOtto-Wilhelm Merten, Sabine Charrier, Nicolas Laroudie, et al.
Ophthalmology|February 11, 2018
Safety of rAAV2/2-ND4 Gene Therapy for Leber Hereditary Optic NeuropathyCatherine Vignal, Scott Uretsky, Serge Fitoussi, et al.
Human Gene Therapy|October 4, 2019
Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System ManufacturingConstanze Radek, Ornellie Bernadin, Katharina Drechsel, et al.
The Journal of Biological Chemistry|September 25, 2003
GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptorCaroline Diveu, Eric Lelièvre, David Perret, et al.
Pageof 11